Therapeutic human papillomavirus vaccines: Current clinical trials and future directions

Expert Opinion on Biological Therapy

Volumn 8, Issue 4, 2008, Pages 421-439

  Hung, Chien Fu ^a,b   Ma, Barbara ^a,b   Monie, Archana ^a,b   Tsen, Shaw Wei ^a,b   Wu, T C ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; HPV; Human papillomavirus; Therapeutic; Vaccines

Indexed keywords

DENDRITIC CELL VACCINE; DNA VACCINE; EPIGALLOCATECHIN GALLATE; HYBRID PROTEIN; PEPTIDE VACCINE; RNA VACCINE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR; WART VIRUS VACCINE; ZYC 101; CANCER VACCINE;

ANTIGEN EXPRESSION; CLINICAL TRIAL; HUMAN; NONHUMAN; PREVALENCE; REVIEW; TUMOR IMMUNITY; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS; FEMALE; IMMUNIZATION; TREATMENT OUTCOME; UTERINE CERVIX TUMOR; VIROLOGY;

ANIMALIA; HUMAN PAPILLOMAVIRUS; MIRIDAE;

CANCER VACCINES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 42149123438     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.4.421     Document Type: Review

References (140)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9 • This paper reports that, worldwide, more than 99% of cervical carcinomas are associated with HPV, suggesting that HPV maybe a cause of cervical cancer
2. Devaraj K, Gillison ML, Wu TC. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med 2003;14:345-62
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
4. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27
5. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802
6. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50
7. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65
8. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8
9. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55
10. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70
11. Bermudez-Humaran LG, Langella P, Miyoshi A, et al. Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol 2002;68:917-22
12. Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004;53:427-33
13. Cortes-Perez NG, Azevedo V, Alcocer-Gonzalez JM, et al. Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target 2005;13:89-98
14. Souders NC, Sewell DA, Pan ZK, et al. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun 2007;7:2. Available from: www.cancerimmunity.org/v7p2/070102.htm
15. Sewell DA, Douven D, Pan ZK, et al. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Orolaryngol Head Neck Surg 2004;130:92-7
16. Sewell DA, Shahabi V, Gunn GR 3rd, et al. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 2004;64:8821-5
17. Monahan SJ, Salgaller ML. Viral vectors for gene transfer into antigen presenting cells. Curr Opin Mol Ther 1999;1:558-64
18. Hsieh CJ, Kim TW, Hung CF, et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 2004;22:3993-4001
19. Lamikanra A, Pan ZK, Isaacs SN, et al. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol 2001;75:9654-64
20. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6
21. Brandsma JL, Shlyankevich M, Zhang L, et al. Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J Virol 2004;78:116-23
22. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, et al. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007;56:997-1007
23. Liu DW, Tsao YP, Kung JT, et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000;74:2888-94
24. Jin HS, Park EK, Lee JM, et al. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecol Oncol 2005;97:559-67
25. Riezebos-Brilman A, Regts J, Freyschmidt EJ, et al. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther 2005;12:1410-4
26. Daemen T, Riezebos-Brilman A, Regts J, et al. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 2004;9:733-42
27. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7
28. Adams M, Borysiewicz L, Fiander A, et al. Clinical studies of human papilloma vaccines in cervical cancer. Adv Exp Med Biol 2001;495:419-27
29. Kaufmann AM, Stern PL, Rankin EM, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002;8:3676-85
30. Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003;63:6032-41
31. Kang TH, Lee JH, Song CK, et al. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 2007;67:802-11
32. Baldwin PJ, van der Burg SH, Boswell CM, et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003;9:5205-13
33. Corona Gurierrez CM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004;15:421-31
34. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006;13:592-7
35. Albarran YCA, de la Garza A, Cruz Quiroz BJ, et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. Biodrugs 2007;21:47-59
36. Roden RB, Monie A, Wu TC. Opportunities to improve the prevention and treatment of cervical cancer. Curr Mol Med 2007;7:490-503
37. Manuri PR, Nehete B, Nehete PN, et al. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 2007;25:3302-10
38. Qin Y, Wang XH, Oui HL, et al. Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice. Gynecol Oncol 2005;96:475-83
39. Zwaveling S, Ferreira Mora SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350-8
40. Chen YF, Lin CW, Tsao YP, Chen SL. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol 2004;78:1333-43
41. Daftarian P, Mansour M, Benoit AC, et al. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006;24:5235-44
42. Vambutas A, DeVoti J, Nouri M, et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005;23:5271-80
43. Ressing ME, van Driel WJ, Brandt RM, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000;23:255-66
44. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999;35:946-52
45. Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6:3406-16
46. Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998;4:2103-9
47. Melief CJ, Welters MJP, Kenter GG, et al. Long peptide vaccine-induced migration of HPV16 specific type 1 and 2T-cells into the lesions of VIN 3 patients. Cancer Immun 2007;7:20
48. Bijker MS, Melief CJ, Offringa R, van der Burg SH. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 2007;6:591-603
49. Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: Therapeutic effect against cervical cancer. Cancer Immunol Immunother 2005;54:1180-90
50. Stewart TJ, Drane D, Malliaros J, et al. ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine 2004;22:3738-43
51. Preville X, Ladant D, Timmerman B, Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005;65:641-9
52. Liao CW, Chen CA, Lee CN, et al. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 2005;65:9089-98
53. Qian X, Lu Y, Liu Q, et al. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Δ/mE7/TBhsp70Δ fusion protein vaccine in an animal model. Immunol Lett 2006;102:191-201
54. Chu NR, Wu HB, Wu T, et al. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000;121:216-25
55. Lacey CJ, Thompson HS, Monteiro EF, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999;179:612-8
56. Thompson HS, Davies ML, Holding FP, et al. Phase 1 safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 1999;17:40-9
57. Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004;23:172-81
58. de Jong A, O'Neill T, Khan AY, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002;20:3456-64
59. Hallez S, Simon P, Maudoux F, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 2004;53:642-50
60. Chu NR. Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease. Expert Opin Biol Ther 2003;3:477-86
61. Palefsky JM, Berry JM, Jay N, et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS (London, England) 2006;20:1151-5
62. Einstein MH, Kadish AS, Burk RD, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007;106:453-60
63. Hung CF, Wu TC. Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther 2003;5:20-4
64. Tsen SW, Paik AH, Hung CF, Wu TC. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines 2007;6:227-39
65. Trimble C, Lin CT, Hung CF, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003;21:4036-42
66. Hung CF, Cheng WF, Chai CY, et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 2001;166:5733-40
67. Hung CF, He L, Juang J, et al. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 2002;76:2676-82
68. Cheung YK, Cheng SC, Sin FW, Xie Y. Plasmid encoding papillomavirus type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine 2004;23:629-38
69. Liu WJ, Gao F, Zhao KN, et al. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology 2002;301:43-52
70. Lin CT Tsai YC, He L, et al. A DNA vaccine encoding a codon-optimized human papillomavims type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 2006;13:481-8
71. Chen C-H, Wang T-L, Hung C-F, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-42
72. Hung CF, Cheng WF, He L, et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 2003;63:2393-8
73. Hung C-F, Hsu K-F, Cheng W-F, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Flt3-ligand. Cancer Res 2001;61:1080-8
74. Hung C-F, Cheng W-F, Hsu K-F, et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001;61:3698-703
75. Kim JW, Hung CF, Juang J, et al. Comparison of HPV DNA vaccines employing intracellular targering strategies. Gene Ther 2004;11:1011-8
76. Huang CH, Peng S, He L, et al. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther 2005;12:1180-6 • This paper describes an innovative strategy for bypassing antigen processing as a method for generating stable antigen presentation in DCs, thus enhancing DNA vaccine potency.
77. Moniz M, Ling M, Hung CF, Wu TC. HPV DNA vaccines. Front Biosci 2003;8:d55-68
78. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995;92:11671-5
79. Ji H, Wang TL, Chen CH, et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 1999;10:2727-40
80. Hung CF, Tsai YC, He L, Wu TC. DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4(+) T-cell immune responses and enhances vaccine potency. Mol Ther 2007;15:1211-9 • This paper describes a novel strategy to enhance DNA vaccine potency by inducing a strong CD4+ T helper cell immune response.
81. Kim TW, Hung CF, Ling M, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003;112:109-17
82. Smahel M, Pokorna D, Mackova J, Vlasak J. Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase. J Gene Med 2004;6:1092-101
83. Kim TW, Hung CF, Boyd D, et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 2003;171:2970-6
84. Kim TW, Hung CF, Boyd DA, et al. Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 2004;64:400-5
85. Kim TW, Hung CF, Zheng M, et al. A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response. J Biomed Sci 2004;11:493-9
86. Kim TW, Lee JH, He L, et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005;65:309-16 • This study presents an innovative strategy to enhance DNA vaccine potency by prolonging DC survival to enhance T cell interaction.
87. Leachman SA, Tigelaar RE, Shlyankevich M, et al. Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus-rabbit model. J Virol 2000;74:8700-8
88. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998;5:231-52
89. Kim MS, Sin JI. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology 2005;116:255-66
90. Sheets EE, Urban RG, Crum CP, et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 2003;188:916-26
91. Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002;8:1028-37 • This study represents the first therapeutic HPV DNA vaccine clinical trial in patients with anal dysplasia.
92. Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004;103:317-26
93. Hariharan MJ, Driver DA, Townsend K, et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 1998;72:950-8
94. Brandsma JL, Shylankevich M, Su Y, et al. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol 2007;81:5749-58
95. Berglund P, Quesada-Rolander M, Putkonen P, et al. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 1997;13:1487-95
96. Berglund P, Smerdou C, Fleeton MN, et al. Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 1998;16:562-5
97. Pushko P, Parker M, Ludwig GV, et al. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997;239:389-401
98. Hsu KF, Hung CF, Cheng WF, et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 2001;8:376-83
99. Kim TW, Hung CF, Juang J, et al. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Ther 2004;11:336-42
100. Cheng WF, Hung CF, Hsu KF, et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 2001;12:235-52
101. Cheng W-F, Hung C-F, Chai C-Y, et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol 2001;75:2368-76
102. Cheng WF, Hung CF, Hsu KF, et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 2002;13:553-68
103. Herd KA, Harvey T, Khromykh AA, Tindle RW. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour. Virology 2004;319:237-48
104. Varnavski AN, Young PR, Khromykh AA. Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol 2000;74:4394-403
105. Santin AD, Bellone S, Roman JJ, et al. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des 2005;11:3485-500
106. Tillman BW, Hayes TL, DeGruijl TD, et al. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 2000;60:5456-63
107. Wang T-L, Ling M, Shih I-M, et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000;7:726-33
108. Mackova J, Kutinova L, Hainz P, et al. Adjuvant effect of dendritic cells transduced with recombinanr vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. Int J Oncol 2004;24:1581-8
109. Peng S, Kim TW, Lee JH, et al. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther 2005;16:584-93
110. Kim TG, Kim CH, Won EH, et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology 2004;112:117-25
111. Santin AD, Bellone S, Gokden M, et al. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 2002;346:1752-3
112. Ferrara A, Nonn M, Sehr P, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003;129:521-30
113. Santin AD, Bellone S, Palmieri M, et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006;100:469-78
114. Bubenik J, Simova J, Hajkova R, et al. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int J Oncol 1999;14:593-7
115. Hallez S, Detremmerie O, Giannouli C, et al. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Im J Cancer 1999;81:428-37
116. Mikyskova R, Indrova M, Simova J, et al. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol 2004;24:161-7
117. Chang EY, Chen CH, Ji H, et al. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000;86:725-30
118. Wlazlo AP, Deng H, Giles-Davis W, Ertl HC. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther 2004;11:457-64
119. Chen CH, Wang TL, Hung CF, et al. Boosting with tecombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000;18:2015-22
120. Rittich S, Duskova M, Mackova J, et al. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2. Oncol Rep 2005;13:311-7
121. Lin CT, Hung CF, Juang J, et al. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther 2003;8:559-66
122. Mackova J, Stasikova J, Kutinova L, et al. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother 2006;55:39-46
123. Christensen ND, Han R, Cladel NM, Pickel MD. Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences. Antimicrob Agents Chemother 2001;45:1201-9
124. Sobotkova E, Duskova M, Smahel M, et al. Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells. Oncol Rep 2004;12:877-83
125. Fiander AN, Tristram AJ, Davidson EJ, et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006;16:1075-81
126. Smyth LJ, Van Poelgeest MI, Davidson EJ, et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 2004;10:2954-61
127. Davidson EJ, Faulkner RL, Sehr P, et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 2004;22:2722-9
128. Bae SH, Park YJ, Park JB, et al. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 2007;13:341-9
129. Ye GW, Park JB, Park YJ, et al. Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. Mol Ther 2007;15:1564-70
130. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-13
131. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56:739-45
132. Goldberg MV, Maris CH, Hipkiss EL, et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007;110:186-92
133. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51
134. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8
135. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10:15-8
136. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004;5:241-51
137. Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997;71:630-7
138. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001;7:1118-22
139. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
140. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007;13:828-35